Athersys to Present at 2014 BIO Asia International Conference

        Print
| Source: Athersys, Inc.

CLEVELAND, March 26, 2014 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Company will present at the 2014 BIO Asia International Conference to be held at the Grand Hyatt in Tokyo, Japan, from April 8-9, 2014.

Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer, will present on Wednesday, April 9, 2014 at 8:30 a.m. Japanese Standard Time. Athersys is also a conference sponsor of the 2014 BIO Asia International Conference.

About BIO Asia

The BIO Asia International Conference is an exclusive, customized partnering forum that brings together U.S. and European drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements. The format and selective nature of the conference makes this the premier, dedicated biotech partnering event in Asia an unrivalled opportunity to meet with the leading international pharmaceutical and biotech companies in one place at one time. At last year's event, over 300 delegates attended from 20 countries, representing more than 160 companies.

About Athersys

Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft-versus-host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products.

William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900


Investor Relations:
Lisa M. Wilson
In-Site Communications
Tel: (917) 543-9932